Steven Valiquette
Stock Analyst at Mizuho
(3.62)
# 806
Out of 5,149 analysts
126
Total ratings
56.92%
Success rate
5.44%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $14 → $16 | $13.43 | +19.14% | 9 | Mar 2, 2026 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $2.08 | +44.58% | 2 | Feb 27, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $81 → $88 | $79.28 | +11.00% | 7 | Feb 25, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $25.37 | +34.04% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $28.36 | -4.78% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $224.40 | +4.72% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $981.97 | -9.88% | 5 | Feb 5, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $180.04 | +11.09% | 13 | Jan 20, 2026 | |
| SOLV Solventum | Upgrades: Outperform | $85 → $100 | $70.97 | +40.91% | 3 | Jan 20, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $43.36 | +10.70% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $28 | $11.97 | +133.92% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $6 | $2.74 | +119.38% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $366.00 | +3.83% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $25.87 | +93.27% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $179.49 | +81.07% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $4.98 | +101.01% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $79.67 | +58.16% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $4.64 | +7.76% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $201.09 | -29.38% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $85.59 | -35.74% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $206.18 | -55.38% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $286.79 | +97.01% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $79.79 | +25.33% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $144.33 | +177.14% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $43.63 | +145.24% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $40.21 | -57.72% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $14.78 | -18.78% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $106.56 | -9.91% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $205.94 | -41.73% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $533.45 | -76.19% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $179.97 | +98.92% | 3 | Dec 6, 2019 |
DENTSPLY SIRONA
Mar 2, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $13.43
Upside: +19.14%
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $2.08
Upside: +44.58%
Henry Schein
Feb 25, 2026
Maintains: Neutral
Price Target: $81 → $88
Current: $79.28
Upside: +11.00%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $25.37
Upside: +34.04%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $28.36
Upside: -4.78%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $224.40
Upside: +4.72%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $981.97
Upside: -9.88%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $180.04
Upside: +11.09%
Solventum
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $70.97
Upside: +40.91%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.36
Upside: +10.70%
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $11.97
Upside: +133.92%
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $2.74
Upside: +119.38%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $366.00
Upside: +3.83%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $25.87
Upside: +93.27%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $179.49
Upside: +81.07%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $4.98
Upside: +101.01%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $79.67
Upside: +58.16%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $4.64
Upside: +7.76%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $201.09
Upside: -29.38%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $85.59
Upside: -35.74%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $206.18
Upside: -55.38%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $286.79
Upside: +97.01%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $79.79
Upside: +25.33%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $144.33
Upside: +177.14%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $43.63
Upside: +145.24%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $40.21
Upside: -57.72%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $14.78
Upside: -18.78%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $106.56
Upside: -9.91%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $205.94
Upside: -41.73%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $533.45
Upside: -76.19%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $179.97
Upside: +98.92%